Amicogen Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Amicogen.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	45.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

Mar 21

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Jan 14

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Dec 30

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Dec 15

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Nov 30

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amicogen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A092040 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	159,904	-23,289	-53,961	8,643	N/A
9/30/2023	164,246	-29,420	-46,637	-2,150	N/A
6/30/2023	160,012	-28,646	-43,848	-655	N/A
3/31/2023	152,966	-36,636	-54,828	-13,409	N/A
12/31/2022	144,296	-47,220	-69,750	-22,413	N/A
9/30/2022	139,504	-39,813	-67,385	-9,831	N/A
6/30/2022	124,834	-61,072	-76,019	-18,895	N/A
3/31/2022	123,766	-3,132	-65,953	-2,198	N/A
12/31/2021	124,881	3,733	-49,122	8,073	N/A
9/30/2021	117,317	33,202	-40,789	1,094	N/A
6/30/2021	122,414	61,569	-13,707	20,234	N/A
3/31/2021	121,274	39,193	-3,428	17,761	N/A
12/31/2020	115,856	31,604	-7,380	8,866	N/A
9/30/2020	129,171	33,394	-15,208	6,315	N/A
6/30/2020	120,536	14,272	-15,537	7,936	N/A
3/31/2020	114,651	-34,074	-24,591	-718	N/A
12/31/2019	115,181	87	-13,220	8,760	N/A
9/30/2019	90,882	9,728	-5,863	14,568	N/A
6/30/2019	94,620	21,428	-9,594	8,271	N/A
3/31/2019	91,338	63,867	-4,400	8,731	N/A
12/31/2018	94,522	40,168	-9,576	2,840	N/A
9/30/2018	99,013	15,834	-8,971	-148	N/A
6/30/2018	89,822	14,603	-5,228	6,697	N/A
3/31/2018	86,089	-3,395	1,334	10,881	N/A
12/31/2017	73,665	-4,606	-925	11,882	N/A
9/30/2017	72,075	533	N/A	13,207	N/A
6/30/2017	67,594	332	N/A	12,017	N/A
3/31/2017	66,193	-626	N/A	12,787	N/A
12/31/2016	68,968	1,589	N/A	11,277	N/A
9/30/2016	64,782	1,630	N/A	12,746	N/A
6/30/2016	57,417	2,098	N/A	10,489	N/A
3/31/2016	46,354	3,248	N/A	14,030	N/A
12/31/2015	32,457	2,066	N/A	12,343	N/A
9/30/2015	24,263	4,816	N/A	5,466	N/A
6/30/2015	26,619	6,774	N/A	5,126	N/A
3/31/2015	27,072	6,846	N/A	4,169	N/A
12/31/2014	27,332	7,563	N/A	4,426	N/A
9/30/2014	24,208	6,327	N/A	5,341	N/A
6/30/2014	22,184	5,412	N/A	5,719	N/A
3/31/2014	23,496	7,019	N/A	6,007	N/A
12/31/2013	23,181	7,575	N/A	6,623	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A092040's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if A092040's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A092040's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A092040's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A092040's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A092040's Return on Equity is forecast to be high in 3 years time

Amicogen Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding

Investor sentiment deteriorated over the past week

Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AG

Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.

Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AG

Amicogen, Inc. announced that it has received KRW 50 billion in funding

Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investors

With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Investor sentiment improved over the past week

Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

New 90-day low: ₩29,700

Is Amicogen (KOSDAQ:092040) A Risky Investment?

New 90-day low: ₩31,700

What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Investor sentiment improved over the past week

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

New 90-day high - ₩42,700

New 90-day high - ₩41,600

New 90-day high - ₩40,400

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies